Angioedema News and Research

RSS
Angioedema is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues. It is very similar to urticaria, but urticaria, commonly known as hives, occurs in the upper dermis.
Dyax reports total revenues of $16.9 million for fourth quarter 2013

Dyax reports total revenues of $16.9 million for fourth quarter 2013

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

BioCryst receives $2.5M to advance development of BCX4430 for Marburg virus disease treatment

BioCryst receives $2.5M to advance development of BCX4430 for Marburg virus disease treatment

Biocryst seeks FDA NDA approval for Peramivir to treat influenza

Biocryst seeks FDA NDA approval for Peramivir to treat influenza

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

EMA expands administration options for Hizentra

EMA expands administration options for Hizentra

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

Oral allergy syndrome sufferers with hypertension may be at increased risk for severe reaction

Oral allergy syndrome sufferers with hypertension may be at increased risk for severe reaction

Anaphylaxis due to shrimp allergy is less than 8% in children

Anaphylaxis due to shrimp allergy is less than 8% in children

Viropharma announces financial results for third quarter 2013

Viropharma announces financial results for third quarter 2013

New smartphone app for patients with hemophilia and related bleeding disorders

New smartphone app for patients with hemophilia and related bleeding disorders

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

FDA expands Hizentra administration options for people with primary immunodeficiency

FDA expands Hizentra administration options for people with primary immunodeficiency